Ascletis Begins Phase Two Diabetes Drug Trial
January 26, 2026 | 11:40
The biopharmaceutical company commenced dosing patients in its thirteen-week American clinical study evaluating an oral GLP-1 receptor agonist for diabetes management.
Ascletis ASC47 Plus Semaglutide 2025: Body Weight Down Fifty Six Point Two Per Cent More
September 22, 2025 | 15:17
Phase II data set up late-stage trials, giving medical writers obesity drug combo keywords and full poster download.
Ascletis ASC40 Phase III 2025: FASN Inhibitor Cuts Acne Lesions Fifty Per Cent
September 18, 2025 | 11:04
Late-breaker at EADV shows once-daily pill beats placebo, giving skincare writers acne drug pipeline keywords and full poster PDF.
Ascletis ASC30 GLP-1R Data 2025: Oral Obesity Drug Cuts Weight Twelve Per Cent
September 17, 2025 | 15:58
Once daily pill rivals injectables, giving diabetes bloggers EASD 2025 keywords and a full poster PDF for search friendly coverage.
Ascletis pill shows once-daily PK win
August 28, 2025 | 18:28
Obesity patients cheer one-tablet hope—yet regulators await Phase III waistlines.
Ascletis Reports Stronger Weight-Loss Results With Dual Agonist Combo
August 18, 2025 | 14:44
Animal study shows ASC47 + ASC31 outperform rival treatments in obesity model.
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025
March 20, 2025 | 18:00
Ascletis Pharma Inc. announces it will host an Obesity Portfolio Webinar on April 2, 2025 , from 9:00 a.m. – 10:30 a.m. ET.
Mobile Version